Category: 3. Business

Running large companies in construction, logistics, energy, and manufacturing requires careful coordination between millions of people, devices, and systems. For more than a decade, Samsara has helped those companies connect their assets to get work done more intelligently.

Founded by John Bicket SM ’05 and Sanjit Biswas SM ’05, Samsara’s platform gives companies with physical operations a central hub to track and learn from workers, equipment, and other infrastructure. Layered on top of that platform are real-time analytics and notifications designed to prevent accidents, reduce risks, save fuel, and more.

Tens of thousands of customers have used Samsara’s platform to improve their operations since its founding in 2015. Home Depot, for instance, used Samsara’s artificial intelligence-equipped dashcams to reduce their total auto liability claims by 65 percent in one year. Maxim Crane Works saved more than $13 million in maintenance costs using Samsara’s equipment and vehicle diagnostic data in 2024. Mohawk Industries, the world’s largest flooring manufacturer, improved their route efficiency and saved $7.75 million annually.

“It’s all about real-world impact,” says Biswas, Samsara’s CEO. “These organizations have complex operations and are functioning at a massive scale. Workers are driving millions of miles and consuming tons of fuel. If you can understand what’s happening and run analysis in the cloud, you can find big efficiency improvements. In terms of safety, these workers are putting their lives at risk every day to keep this infrastructure running. You can literally save lives if you can reduce risk.”

Finding big problems

Biswas and Bicket started PhD programs at MIT in 2002, both conducting research around networking in the Computer Science and Artificial Intelligence Laboratory (CSAIL). They eventually applied their studies to build a wireless network called MIT RoofNet.

Upon graduating with master’s degrees, Biswas and Bicket decided to commercialize the technologies they worked on, founding the company Meraki in 2006.

“How do you get big Wi-Fi networks out in the world?” Biswas asks. “With MIT RoofNet, we covered Cambridge in Wi-Fi. We wanted to enable other people to build big Wi-Fi networks and make Wi-Fi go mainstream for larger campuses and offices.”

Over the next six years, Meraki’s technology was used to create millions of Wi-Fi networks around the world. In 2012, Meraki was acquired by Cisco. Biswas and Bicket left Cisco in 2015, unsure of what they’d work on next.

“The way we found ourselves to Samsara was through the same curiosity we had as graduate students,” Biswas says. “This time it dealt more with the planet’s infrastructure. We were thinking about how utilities work, and how construction happens at the scale of cities and states. It drew us into operations, which is the infrastructure backbone of the planet.”

As the founders learned about industries like logistics, utilities, and construction, they realized they could use their technical background to improve safety and efficiency.

“All these industries have a lot in common,” Biswas says. “They have a lot of field workers — often thousands of them — they have a lot of assets like trucks and equipment, and they’re trying to orchestrate it all. The throughline was the importance of data.”

When they founded Samsara 10 years ago, many people were still collecting field data with pen and paper.

“Because of our technical background, we knew that if you could collect the data and run sophisticated algorithms like AI over it, you could get a ton of insights and improve the way those operations run,” Biswas says.

Biswas says extracting insights from data is easy. Making field-ready products and getting them into the hands of frontline workers took longer.

Samsara started by tapping into existing sensors in buildings, cars, and other assets. They also built their own, including AI-equipped cameras and GPS trackers that can monitor driving behavior. That formed the foundation of Samsara’s Connected Operations Platform. On top of that, Samsara Intelligence processes data in the cloud and provides insights like ways to calculate the best routes for commercial vehicles, be more proactive with maintenance, and reduce fuel consumption.

Samsara’s platform can be used to detect if a commercial vehicle or snowplow driver is on their phone and send an audio message nudging them to stay safe and focused. The platform can also deliver training and coaching.

“That’s the kind of thing that reduces risk, because workers are way less likely to be distracted,” Biswas says. “If you do for millions of workers, you reduce risk at scale.”

The platform also allows managers to query their data in a ChatGPT-style interface, asking questions such as: Who are my safest drivers? Which vehicles need maintenance? And what are my least fuel-efficient trucks?

“Our platform helps recognize frontline workers who are safe and efficient in their job,” Biswas says. “These people are largely unsung heroes. They keep our planet running, but they don’t hear ‘thank you’ very often. Samsara helps companies recognize the safest workers on the field and give them recognition and rewards. So, it’s about modernizing equipment but also improving the experience of millions of people that help run this vital infrastructure.”

Continuing to grow

Today Samsara processes 20 trillion data points a year and monitors 90 million miles of driving. The company employs about 4,000 people across North America and Europe.

“It still feels early for us,” Biswas says. “We’ve been around for 10 years and gotten some scale, but we needed to build this platform to be able to build more products and have more impact. If you step back, operations is 40 percent of the world’s GDP, so we see a lot of opportunities to do more with this data. For instance, weather is part of Samsara Intelligence, and weather is 20 to 25 percent of the risk, and so we’re training AI models to reduce risk from the weather. And on the sustainability side, the more data we have, the more we can help optimize for things like fuel consumption or transitioning to electric vehicles. Maintenance is another fascinating data problem.”

The founders have also maintained a connection with MIT — and not just because the City of Boston’s Department of Public Works and the MBTA are customers. Last year, the Biswas Family Foundation announced funding for a four-year postdoctoral fellowship program at MIT for early-stage researchers working to improve health care.

Biswas says Samsara’s journey has been incredibly rewarding and notes the company is well-positioned to leverage advances in AI to further its impact going forward.

“It’s been a lot of fun and also a lot of hard work,” Biswas says. “What’s exciting is that each decade of the company feels different. It’s almost like a new chapter — or a whole new book. Right now, there’s so many incredible things happening with data and AI. It feels as exciting as it did in the early days of the company. It feels very much like a startup.”

Tokyo, January 16, 2026 – Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has expanded its lineup for the KXZ3 Series of building-use multi-split air-conditioners which use low-environmental impact R32 refrigerant, in response to increasing demand in overseas markets, and begun mass production. To complement the existing three units in 22.4-33.5 kW models, a total of seven units in 40.0-67.0 kW range have been added in response to increasing demand in overseas markets. Sales will begin this spring in Europe, with sequential sales launches in Australia, New Zealand, and Turkey.

With the addition of the units, the maximum system capacity, which had been 168.0 kW in a combination of three individual 56.0 kW models with the existing KXZ2 Series, has been expanded to 201.0 kW. In addition, this series, by flexibly combining up to three models, can be used to build an optimal air conditioning system best suited to installation conditions and operational purposes. For example, in environments with numerous restrictions, such as buildings in urban centers, a space-saving installation is possible even with the same capacity by selecting unit combinations that reduce the required installation footprint. Meanwhile, selecting high-efficiency unit combination enhances energy-saving performance and operating efficiency, helping to reduce running costs over the long term. All models have a uniform height of 1,750 mm, which gives a sense of unity to the external appearance, and makes it easy to connect the units, design piping, and install and maintain systems.

In addition, this series significantly reduces a system’s environmental impact. Compared to the KXZ2 Series, which uses R410A refrigerant with a global warming potential (GWP)(Note1) of 2,088, the KXZ3 series uses R32 refrigerant, which has a GWP of 675, or about one-third that of the previous series. In terms of functionality, the energy efficiency has been improved with a new type of compressor and renewed air flow path design. Further, a “Variable Temperature & Capacity Control +” function has been added for a balance energy savings and indoor comfort, as well as a “hot gas bypass defrost” operating mode that lessens the fall in indoor temperature common with conventional defrosting operation.(Note2) MHI Thermal Systems also offers a lineup of dedicated safety devices that comply with European safety regulations. One such device, a shut-off valve that blocks the flow of refrigerant in the event of a refrigerant leak or other abnormality, is designed to accommodate multiple indoor units, helping to reduce installation costs.

Consideration has also been given to the design. The 22.4-33.5 kW models released in Fiscal 2024 as the KXZ3 Series were highly praised for their exterior design that harmonizes with urban spaces, as well as their ability to reduce the environmental impact and achieve high energy savings. The series is characterized by a design that blends with the exterior environment, such as blue ornamentation, rounded corners, and flat panel surfaces, as well as its environmental performance. In recognition of this overall value, the KXZ3 Series received the A’ Design Award 2025,(Note3) and the Australian Good Design Award.(Note4) The models added to the lineup also adhere to this design concept, achieving an integrated design with a sense of unity in their external appearance, even with combinations of units with different capacities or a large number of units.

Going forward, MHI Thermal Systems will continue to offer solutions that combine energy efficiency and comfort in its air-conditioning business, including packaged and building-use air-conditioners for overseas markets, and contribute to the realization of carbon neutrality.

• 1Global Warming Potential (GWP) is a coefficient of the greenhouse effect of a gas relative to carbon dioxide (CO₂), which has a fixed GWP of 1.0. Smaller values indicate a lower greenhouse effect, and better environmental performance.
• 2Conventional defrosting removes frost formed on the outdoor unit during heating operation. Because the airflow of the indoor unit stops during this operation, the indoor temperature may fall temporarily depending on the building conditions.
• 3For more information on the awards received at A’ Design Award 2025, see the following press release.
  https://www.mhi.com/news/25060401.html
• 4For more information on the receipt of the Australian Good Design Award, see the following press release.
  https://www.mhi.com/news/25101701.html

SHANGHAI and HONG KONG, Jan. 15, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 (a CLDN18.2 antibody-drug conjugate [ADC]), as well as R&D progress on ATG-125 (a B7-H3 x PD-L1 bispecific ADC), its steric hindrance masking AnTenGager™ T cell engager (TCE) platform, and other key preclinical programs.

1. Core Clinical Program: ATG-022

• Latest data from the Phase I/II CLINCH study: As of December 25, 2025, among patients with moderate to high CLDN18.2 expression (IHC 2+ > 20%) in the 2.4 mg/kg dose cohort, the objective response rate (ORR) was 40% (12/30) and the disease control rate (DCR) was 90% (27/30), with a median progression-free survival (mPFS) of 5.09 months and a median overall survival (mOS) of 14.72 months. In the 1.8 mg/kg dose cohort, the ORR was 46.7% (14/30), the DCR was 86.7% (26/30), the mPFS was 6.97 months, and the mOS has not yet been reached. Among patients with low/ultra-low CLDN18.2 expression (IHC 2+ ≤ 20%) treated at the efficacious dose range of 1.8-2.4 mg/kg, the ORR was 28.6% (6/21). In addition, one patient in each of the three dose groups achieved a complete response (CR). These results demonstrated the potent anti-tumor activity of ATG-022 across all levels of CLDN18.2 expression.
• Promising frontline combination potential: Compared with the data presented at the Company’s R&D Day in November last year, the 1.8 mg/kg dose group demonstrated a further improvement in ORR and a meaningful prolongation in mPFS, while maintaining a favorable safety profile. The incidence of Grade 3 or higher treatment-related adverse events (TRAEs) was only 19.4%. This differentiated safety profile positions ATG-022 as a potentially best-in-class ADC in terms of safety, with the potential to be combined with checkpoint inhibitors (CPIs) and chemotherapy to transform the current frontline standard-of-care regimen.
• First Disclosure of Positive Clinical Signals of ATG-022 in Non-Gastrointestinal Tumors: As of January 6, 2025, among 9 efficacy evaluable patients, the ORR was 22.2% (2/9), and DCR was 88.9% (8/9). These data suggest that ATG-022 may have the potential to treat CLDN18.2-positive non-gastrointestinal tumors, which could expand the treatable patient population beyond gastrointestinal cancers. The efficacy observed to date also supports further exploration of CLDN18.2 as a pan-tumor therapeutic target.
• Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and the Phase Ib/II CLINCH-2 study of ATG-022 in Mainland of China and Australia. The Company continues to advance the clinical development of ATG-022 across different lines of gastric cancer treatment, including first-line therapy in combination with checkpoint inhibitors (CPIs) and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with CPIs; and third-line therapy as monotherapy, covering patients with varying levels of CLDN18.2 expression. In addition, the CLINCH study of ATG-022 includes a basket trial cohort evaluating multiple tumor types, with the majority of patients continuing to receive treatment.

2. Next-Generation ADCs and Proprietary TCEs

ATG-125 (B7-H3 × PD-L1 bispecific ADC): ATG-125 is an “IO+ADC ” dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of immuno-oncology (IO) therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive signaling, ATG-125 effectively activates T cells and induces immunological memory. Preclinical studies demonstrate that the bispecific ADC delivers superior in vivo efficacy compared with single-target B7-H3-ADC or PD-L1-ADC approaches. The Company plans to submit an IND for ATG-125 in Q1 2027.

TCE platform with steric hindrance masking technology: AnTenGager™ is Antengene’s proprietary, second-generation T cell engager (TCE) platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune diseases, solid tumors and hematological malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:

• ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel “2+1” CD19-targeted T-cell engager developed on the AnTenGager^™ TCE platform for the treatment of B cell related autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology (ACR) Annual Meeting showed that in non-human primate (NHP) models, the monkey surrogate of ATG-201 achieved deep and durable depletion of naïve B cells with a favorable safety profile, characterized by only a very mild and transient increase in cytokine levels. The IND-enabling study of ATG-201 has been completed and the IND-submission is under preparation.
• ATG-106 (CDH6 x CD3 TCE): A global first-in-class CDH6 x CD3 targeted TCE being developed for the treatment of ovarian cancer and kidney cancer. The Company plans to submit an IND for ATG-106 in the first half of 2027.
• ATG-112 (ALPPL2 x CD3 TCE): A global first-in-class ALPPL2 x CD3 targeted TCE being developed for the treatment of gynecologic tumor, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The Company has nominated a preclinical candidate (PCC) in January 2026.
• Additional TCE programs for solid tumors: Antengene plans to submit an IND for ATG-110 (LY6G6D × CD3 TCE) in the first half of 2027 for the treatment of microsatellite-stable colorectal cancer. In addition, ATG-115 (an undisclosed bispecific antibody) and two undisclosed trispecific antibody programs are currently in preclinical development.

3. Innovative Treatment for Autoimmune Diseases: Globally First-in-Class ATG-207

ATG-207 is a globally first-in-class dual-function biologic being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present the preclinical data for ATG-207 for the first time at an international scientific conference in 2026.

About Antengene

Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC) , ATG-037 (oral CD73 inhibitor) , ATG-101 (PD-L1 × 4-1BB bispecific antibody) , ATG-031 (CD24-targeting macrophage activator) , and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor) , is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: [email protected] 

BD Contacts:
Ariel Guo
E-mail: [email protected] 

SOURCE Antengene Corporation Limited

(Bloomberg) — Asia’s tech-led rally pushed to new highs after strong earnings from a chip bellwether eased worries about overheating in the artificial intelligence sector and encouraged investors to add bets.

The MSCI Asia Pacific Index climbed 0.4% on Friday to a record and was set for a fourth weekly gain. A regional gauge of technology shares and South Korea’s benchmark index — a poster-child for the AI theme — also hit all-time highs as Taiwan Semiconductor Manufacturing Co. rose to its highest ever after blowout results.

TSMC’s earnings rekindled enthusiasm for stocks, helping US equities rebound from their first back-to-back losses of the year. That optimism looked set to continue with futures for the S&P 500 and the Nasdaq 100 rising 0.2%. Elsewhere, the yen gained against the dollar after Japan’s finance minister said she’s concerned about the currency’s weakness. Oil steadied after its biggest decline since June, while gold and silver edged lower.

Stocks are extending gains as investors regain confidence in the durability of the tech rally, a key bull-market driver, after concerns over stretched valuations and heavy investment. Comments from TSMC also helped ease worries about the sustainability of data-center spending following a recent pullback in richly valued technology shares.

“Technology stocks had looked vulnerable in recent weeks as investors rotated away from megacap names and into more cyclical areas of the market,” said Fawad Razaqzada at Forex.com. “TSMC’s update, though, appears to have stabilized that ‘rotation’ rather than reversed it outright.”

As Asian shares keep rising, a key relationship they have with currencies is flashing a signal for global funds to rethink their investment strategy in the region.

The 30-day correlation between the MSCI Asia Pacific Index and the Bloomberg Asia Dollar Index — which typically move in lockstep — has dipped below zero for the first time since September 2024.

In other corners of the market, Treasuries were little changed in Asia after falling in US trading when jobless claims unexpectedly dropped to the lowest since November.

The 10-year’s yield is headed for a fifth straight week of minimal change, rivaling its longest stretch of inertia in the past two decades.

The trend — a function primarily of expected stability in US monetary policy — is stoking anxiety among bond-market investors because previous instances of constricted yield ranges have been followed by selloffs.

Traders will also be watching the rising tensions in the Middle East after Fox News reported that at least one US aircraft carrier is moving to the region. US military planners are preparing a range of options depending on the actions of the Iranian government in the next few days, Fox reported.

Separately, the US and Taiwan agreed to a long-sought trade pact that would lower tariffs on goods from the self-governed island to 15% and see Taiwanese semiconductor companies increase financing for American operations by $500 billion.

In Asia, focus is also on Japan, where central bank officials are closely watching the yen’s potential influence on inflation.

Most Bank of Japan watchers judge that Governor Kazuo Ueda and his colleagues have been slow in ratcheting up interest rates, and expect the next move still to be several months away in their base case scenarios.

Traders are also parsing capital flows in and out of Japan Friday as the yen inches toward the 160-per-dollar mark.

Official intervention to strengthen the currency is a topic of discussion among market participants as the yen trades near a one-and-a-half-year low. The yen was a touch stronger at 158.40 against the dollar on Friday.

“We have obviously previously seen Japan intervene above the 160 level and as we get closer to that, I think that becomes a possibility,” said Divya Devesh, co-head of FX research for Asean and South Asia at Standard Chartered. “It is an unstable equilibrium,” he said of Japan’s macro backdrop.

Corporate Highlights:

Goldman Sachs is set to raise $16 billion with the largest investment-grade bond sale ever from a Wall Street bank. China Vanke Co.’s bonds extended their rally, a day after the distressed developer unveiled sweetened proposals to extend payments on some notes. Ford Motor Co. is in talks with China’s BYD Co. about potentially supplying batteries for hybrid vehicles to the American automaker’s overseas factories. Walmart Inc. said Kathryn McLay, chief executive officer of the company’s international business, is stepping down. Some of the main moves in markets:

Stocks

S&P 500 futures rose 0.2% as of 11:53 a.m. Tokyo time Japan’s Topix fell 0.3% Australia’s S&P/ASX 200 rose 0.5% Hong Kong’s Hang Seng fell 0.1% The Shanghai Composite fell 0.1% Euro Stoxx 50 futures fell 0.3% Currencies

The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1611 The Japanese yen rose 0.2% to 158.29 per dollar The offshore yuan was little changed at 6.9641 per dollar Cryptocurrencies

Bitcoin was little changed at $95,484.42 Ether was little changed at $3,300.03 Bonds

The yield on 10-year Treasuries was little changed at 4.16% Japan’s 10-year yield advanced 1.5 basis points to 2.175% Australia’s 10-year yield advanced two basis points to 4.70% Commodities

West Texas Intermediate crude fell 0.2% to $59.10 a barrel Spot gold fell 0.4% to $4,595.41 an ounce This story was produced with the assistance of Bloomberg Automation.

–With assistance from Ruth Carson.

©2026 Bloomberg L.P.

Flying cars are no longer a science fiction fantasy, but are becoming a reality.

They are currently in production and could be delivered to customers within the next year or two.

The company is called Alef Aeronautics.

Founded in 2015, it is at the forefront of the flying car industry, with more than 3,500 pre-orders of its flying cars.

The Alef Model A Ultralight is a vehicle that can drive and fly, as seen in a testing video where the vehicle elevates and goes airborne over another car.

The video has over 2 billion views worldwide.

“A little under a month ago, we started building the first car to be delivered to the actual customer,” said Jim Dukhovny.

Alef Aeronautics co-founder Jim Dukhovny said his company and technology have two priorities: safety and regulatory compliance.

Dukhovny said this vehicle will be able to elevate thousands of feet or just 20.

“At this point at least, the cabin is not pressurized. So you can’t go up to the levels where you need a pressurized cabin,” he said.

Dukhovny said the current Model A ultralight goes for $300,000.

But he expects in about a decade, the price will drop to roughly $30,000.

He called it an EV car first, an aircraft second, with a range of 200 miles on the road and 110 in the air.

It will fall under existing ultra light aircraft Federal Aviation Administration regulations, which means no certification is required currently.

“There are rules where you can take off and land. So if you’re imagining a scenario that you’re going to drive on the freeway, take off, fly, and then land on the freeway, that’s not going to happen,” he said.

He said learning to operate the vehicle will only take a few hours, but also require to learn FAA regulations.

“So you have to read the sectional map, you have to understand the alpha, bravao airspace and where you can fly, where you cannot fly,” he added.

The first models are expected to hit the roadways in either Silicon Valley or Hong Kong and will test real world conditions under very controlled testing.

Bloomberg via Getty Images